INN stock closed at $6.71 on January 31, 2025, down 0.74% for the day. Bullish sentiment stems from Innocan Pharma's innovative LPT-CBD technology, which has shown promising results in preclinical trials and received FDA recognition, positioning the company for growth in veterinary and human chronic pain management. With its recent advancements and regulatory milestones, the stock could see upward momentum, targeting $7.50 in the near term if positive developments continue.